Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | BTK | Q06187 | 6/20 | 0.52 |
| ▸ | ATR | Q13535 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655576 | 0.84 | JAK2 (0.55) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL16655486 | 0.84 | JAK3 (0.55) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL16655526 | 0.84 | JAK2 (0.55) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL23917210 | 0.78 | JAK2 (0.55) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL23917257 | 0.73 | JAK2 (0.47) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL16655634 | 0.72 | ATR (0.66) | JAK2BTKATRPIK3CD | |
| SCHEMBL17267664 | 0.71 | JAK2 (0.77) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL16656038 | 0.70 | PIK3CD (0.62) | JAK3EGFRBTKATRPIK3CD | |
| SCHEMBL13308581 | 0.70 | EGFR (0.89) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL16655658 | 0.70 | ATR (0.71) | BTKATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | JAK2 38/4885JAK3 124/4885JAK1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.